RE-MIND2: Comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma Journal Article
| Authors: | Nowakowski, G. S.; Yoon, D. H.; Mondello, P.; Joffe, E.; Peters, A.; Fleury, I.; Greil, R.; Ku, M.; Marks, R.; Kim, K.; Zinzani, P. L.; Trotman, J.; Sabatelli, L.; Waltl, E. E.; Winderlich, M.; Sporchia, A.; Kurukulasuriya, N. C.; Cordoba, R.; Hess, G.; Salles, G. |
| Article Title: | RE-MIND2: Comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma |
| Abstract: | Abstract: RE-MIND2 (NCT04697160) compared patient outcomes from the L-MIND (NCT02399085) trial of tafasitamab+lenalidomide with those of patients treated with other therapies for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are autologous stem cell transplant ineligible. We present outcomes data for three pre-specified treatments not assessed in the primary analysis. Data were retrospectively collected from sites in North America, Europe, and the Asia Pacific region. Patients were aged ≥18 years with histologically confirmed DLBCL and received ≥2 systemic therapies for DLBCL (including ≥1 anti-CD20 therapy). Patients enrolled in the observational and L-MIND cohorts were matched using propensity score-based 1:1 nearest-neighbor matching, balanced for six covariates. Tafasitamab+lenalidomide was compared with polatuzumab vedotin+bendamustine+rituximab (pola-BR), rituximab+lenalidomide (R2), and CD19-chimeric antigen receptor T-cell (CAR-T) therapies. The primary endpoint was overall survival (OS). Secondary endpoints included treatment response and progression-free survival. From 200 sites, 3,454 patients were enrolled in the observational cohort. Strictly matched patient pairs consisted of tafasitamab+lenalidomide versus pola-BR (n = 24 pairs), versus R2 (n = 33 pairs), and versus CAR-T therapies (n = 37 pairs). A significant OS benefit was observed with tafasitamab+lenalidomide versus pola-BR (HR: 0.441; p = 0.034) and R2 (HR: 0.435; p = 0.012). Comparable OS was observed in tafasitamab+lenalidomide and CAR-T cohorts (HR: 0.953, p = 0.892). Tafasitamab+lenalidomide appeared to improve survival outcomes versus pola-BR and R2, and comparable outcomes were observed versus CAR-T. Although based on limited patient numbers, these data may help to contextualize emerging therapies for R/R DLBCL. Clinical trial registration: NCT04697160 (January 6, 2021) © 2023, The Author(s). |
| Keywords: | lenalidomide; dlbcl; relapsed/refractory; real-world; tafasitamab |
| Journal Title: | Annals of Hematology |
| Volume: | 102 |
| Issue: | 7 |
| ISSN: | 0939-5555 |
| Publisher: | Springer |
| Date Published: | 2023-07-01 |
| Start Page: | 1773 |
| End Page: | 1787 |
| Language: | English |
| DOI: | 10.1007/s00277-023-05196-4 |
| PUBMED: | 37171597 |
| PROVIDER: | scopus |
| PMCID: | PMC10261238 |
| DOI/URL: | |
| Notes: | Article -- Erratum issued, see DOI: 10.1007/s00277-023-05321-3 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work